Zacks Investment Research upgraded shares of VYNE Therapeutics (NASDAQ:VYNE – Get Rating) from a hold rating to a buy rating in a research note published on Wednesday, Zacks.com reports. The brokerage currently has $0.50 price objective on the stock.
According to Zacks, “VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company’s product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey. “
Separately, Cantor Fitzgerald reissued an overweight rating on shares of VYNE Therapeutics in a report on Friday, March 18th.
VYNE Therapeutics (NASDAQ:VYNE – Get Rating) last issued its quarterly earnings results on Thursday, March 17th. The company reported ($0.22) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.22). VYNE Therapeutics had a negative net margin of 444.88% and a negative return on equity of 103.25%. The firm had revenue of $2.29 million during the quarter, compared to the consensus estimate of $4.09 million. As a group, sell-side analysts anticipate that VYNE Therapeutics will post -0.63 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the company. Beacon Pointe Advisors LLC bought a new position in shares of VYNE Therapeutics during the 1st quarter worth about $49,000. Renaissance Technologies LLC lifted its holdings in shares of VYNE Therapeutics by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 965,098 shares of the company’s stock worth $627,000 after acquiring an additional 60,567 shares during the period. Mackenzie Financial Corp bought a new position in shares of VYNE Therapeutics during the 1st quarter worth about $42,000. Bailard Inc. bought a new position in shares of VYNE Therapeutics during the 1st quarter worth about $91,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of VYNE Therapeutics by 175.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 115,698 shares of the company’s stock worth $118,000 after acquiring an additional 73,642 shares during the period. 22.24% of the stock is owned by institutional investors.
VYNE Therapeutics Company Profile (Get Rating)
VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis.
- Get a free copy of the StockNews.com research report on VYNE Therapeutics (VYNE)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.